Aethlon Medical Inc
Company Profile
Business description
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.
Contact
11555 Sorrento Valley Road
Suite 203
San DiegoCA92121
USAT: +1 619 941-0360
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 March 2027
Employees
9
Stocks News & Analysis
stocks
Avoid this overvalued ASX lithium producer
stocks
Morningstar's verdict on SpaceX
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,012.60 | 10.70 | 0.12% |
| CAC 40 | 8,388.84 | 48.13 | 0.58% |
| DAX 40 | 24,697.01 | 196.57 | -0.79% |
| Dow JONES (US) | 51,979.97 | 313.13 | 0.61% |
| FTSE 100 | 10,460.84 | 31.99 | 0.31% |
| HKSE | 23,412.18 | 75.90 | 0.33% |
| NASDAQ | 25,785.34 | 198.30 | 0.78% |
| Nikkei 225 | 69,174.97 | 613.41 | -0.88% |
| NZX 50 Index | 13,400.66 | 35.11 | -0.26% |
| S&P 500 | 7,412.99 | 47.53 | 0.65% |
| S&P/ASX 200 | 8,808.40 | 7.00 | 0.08% |
| SSE Composite Index | 4,110.81 | 4.56 | 0.11% |